-
TRAP-1 Reactivates p53Y220C Through Proximity
2026-09-11
The preprint Activating p53Y220C with a Mutant-Specific Small Molecule describes TRAP-1, a chemical inducer of proximity that brings mutant p53 and BRD4 together to restore p53-dependent transcription. In p53Y220C-expressing pancreatic cell lines, this mechanism increased p21 and other target genes while suppressing cell growth, providing a proof of concept for proximity-based reactivation of mutant tumor suppressors.
-
Fucoidan as an Assay-Design Tool in Cancer Research
2026-09-10
Fucoidan is a Sulfated α-L-Fucan whose anticancer activity depends on context, molecular structure, and assay selection. This guide converts evidence from breast and prostate cancer models into a practical framework for designing orthogonal, mechanism-aware experiments.
-
YM 58483 (BTP2): An Assay-First SOCE Guide
2026-09-10
YM 58483 (BTP2) is a powerful tool for dissecting sustained store-operated calcium entry in immune and fibrosis models. This assay-first guide explains how to connect SOCE inhibition with NFAT, IL-2, ORAI2, and TGF-β1 readouts without confusing pathway dependence with channel identity.
-
DEV VP26, MYH9, and the Actin–Myosin II Network
2026-09-09
This 2025 study combines VP26 interactome profiling with functional perturbation to identify the host actin–myosin II network as a regulator of duck enteritis virus proliferation. Its findings connect viral capsid-protein interactions with MYH9-dependent cytoskeletal function and provide a framework for testing actin-dependent steps in herpesvirus infection.
-
Latrunculin A: Actin Disruption Workflow
2026-09-09
Latrunculin A provides reversible control over actin assembly for rapid cytoskeleton disaggregation, morphology profiling, and mechanistic infection studies. This workflow connects dose–time optimization with orthogonal MYH9 and myosin II assays to separate cytoskeletal effects from nonspecific toxicity.
-
ABT-263 (Navitoclax): Reliable Apoptosis Assays
2026-09-08
This scenario-based guide shows how ABT-263 (Navitoclax), SKU A3007, can improve interpretation of viability, metabolic, and apoptosis experiments. It connects Bcl-2-family biology with practical solvent, storage, endpoint, and vendor-selection decisions for reproducible cancer research workflows.
-
Angiotensin II: From GPCR Signaling to Translation
2026-09-08
A translational guide to Angiotensin II and Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, connecting AT1R-linked signaling with vascular remodeling, hypertension research, abdominal aortic aneurysm models, and carefully bounded insights from SARS-CoV-2 entry research.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-09-07
The reference study shows that puerarin enhances osteogenic differentiation in rat dental follicle cells while increasing nitric oxide, cGMP, and osteogenic marker expression. Pharmacological inhibition with L-NMMA supports a functional role for nitric oxide signaling and provides a useful framework for studying periodontal regeneration.
-
Lipid Nanoparticles Direct Tissue-Specific T Cell Immunity
2026-09-07
This study shows that lipid nanoparticle composition can determine whether intramuscularly injected mRNA remains near the injection site or reaches organs such as the liver and lungs. The resulting differences in antigen expression shape tissue-localized CD8+ T-cell responses, including liver-resident immunity with improved control of liver tumors in mice.
-
GKT137831: Dual Nox1/Nox4 Redox Workflow
2026-09-05
GKT137831 provides a practical way to interrogate Nox1/Nox4-driven oxidative signaling across vascular, fibrotic, and metabolic disease models. This workflow pairs upstream reactive oxygen species measurements with late membrane-damage assays, helping researchers distinguish oxidant generation from ferroptotic execution.
-
CH 223191: Aryl Hydrocarbon Receptor Antagonist
2026-09-04
CH 223191 is a potent aryl hydrocarbon receptor antagonist that blocks TCDD-induced transcriptional activation at approximately 30 nM in cell-based assays. Its defined activity, formulation data, and in vivo effects on CYP1A1 and TCDD-associated toxicity support its use in AhR signaling pathway inhibitor studies and environmental toxicology research.
-
c-Myc:MAX Inhibition as a Translational Strategy
2026-09-04
The c-Myc:MAX complex is more than an oncogenic transcriptional switch: it can connect signaling, chromatin state, telomerase regulation, cell-cycle control, and apoptosis. This article examines how 10058-F4 can help translational researchers test that network across acute myeloid leukemia, prostate cancer, and human pluripotent stem-cell models while keeping mechanistic and pharmacological limitations in view.
-
Polybrene: Smarter Viral Transduction Workflows
2026-09-03
Polybrene (Hexadimethrine Bromide) improves viral attachment and uptake while also supporting lipid-mediated DNA delivery and selected biochemical assays. This practical guide connects reproducible Polybrene workflows with the mitochondrial TCAIM–OGDH findings, showing where the product can help—and where independent validation remains essential.
-
Y-27632: A Mechanistic Guide to ROCK Experiments
2026-09-03
Y-27632 is a selective ROCK inhibitor for dissecting cytoskeletal dynamics, cell-state effects, and assay confounders. This guide connects ROCK perturbation with new APEX2–TERT findings to improve experimental interpretation in stem cell and cancer biology research.
-
Chloroquine Pharmacogenomics: Evidence and Risks
2026-09-02
This review synthesizes evidence that CYP2C8, CYP3A4/5, and CYP2D6 variation may influence chloroquine and hydroxychloroquine exposure, efficacy, and toxicity. Its main translational contribution is a risk-phenotype framework that highlights potential differences among ultra-rapid and poor metabolizers while emphasizing the limited clinical evidence available for genotype-guided treatment.